3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Conditions
Melanoma
114
Carcinoma, Non-Small-Cell Lung
34
Neoplasms
26
Neoplasm Metastasis
19
Prostatic Neoplasms
18
Uveal Melanoma
16
Carcinoma, Renal Cell
16
Lung Neoplasms
14
Pancreatic Neoplasms
13
Diabetes Mellitus, Insulin-Dependent, 12
12
Small Cell Lung Carcinoma
11
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
9
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Sarcoma
7
Carcinoma, Transitional Cell
7
Brain Neoplasms
7
Stomach Neoplasms
6
Mesothelioma
6
Kidney Neoplasms
6
Head and Neck Neoplasms
6
Advanced Cancer
6
Urinary Bladder Neoplasms
5
Recurrence
5
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Interventions
Nivolumab
4
Ipilimumab
3
relatlimab
1
daratumumab
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Various Advanced Cancer
×
Ipilimumab
×
Clear all
NCT03143153
2026-02-17
CheckMate 648
Bristol-Myers Squibb
Phase 3
Completed
970 enrolled
15 charts
1 FDA
NCT02488759
2023-11-13
CheckMate358
Bristol-Myers Squibb
Phase 1/2
Completed
578 enrolled
19 charts
NCT03130959
2022-08-09
CheckMate 908
Bristol-Myers Squibb
Phase 2
Completed
166 enrolled
33 charts